CDKN2A/B, which encodes CDK4/6 inhibitors p16 and p15, is inactivated by mutations or hypermethylation in a subset of ccRCC, and CDKN2A/B loss cooperates with VHL loss to promote ccRCC in mice (4, 26, 54, 55). The gene discussed is CDKN2A; the disease is nonpapillary renal cell carcinoma.